1210344-57-2Relevant articles and documents
AN IMPROVED PURIFICATION PROCESS FOR THE PREPARATION OF ERTUGLIFLOZIN AND ERTUGLIFLOZIN L-PYROGLUTAMIC ACID CO-CRYSTAL
-
Page/Page column 18; 17, (2022/01/04)
The present invention relates to an improved purification process for the preparation of Ertugliflozin (I) and its further conversion to Ertugliflozin L-pyroglutamic acid (L-PGA) co-crystal (II).
AN EFFICIENT PROCESS FOR THE PREPARATION OF ERTUGLIFLOZIN L-PYROGLUTAMIC ACID AND INTERMEDIATES THEREOF
-
Page/Page column 5; 16; 19; 20, (2021/07/10)
The present invention relates to an efficient process for the preparation of Ertugliflozin L-pyroglutamic acid of formula (I) and intermediate thereof, in environment friendly conditions. The present invention further relates to a process for the preparation of substantially pure intermediate of formula (IV).
AMORPHOUS ERTUGLIFLOZIN AND PROCESS FOR ITS PREPARATION
-
, (2020/12/13)
An amorphous form of ertugliflozin and process for its preparation is described. A solid form of ertugliflozin and process for preparation thereof is also described.
A NOVEL PROCESS FOR THE PREPARATION OF SGLT-2 INHIBITORS
-
, (2020/01/24)
The present invention relates to a novel process for the preparation of SGLT-2 inhibitors via addition of a hydroxymethylene group in an open chain intermediate, readily accessible from D-glucose.
Glucopyranosyl derivative and its use in medicine (by machine translation)
-
Paragraph 0685-0688, (2018/07/28)
The invention relates to a as sodium-dependent glucose transporter (SGLTs) inhibitors of the glucopyranosyl derivative, containing the pharmaceutical composition and its use in medicine, in particular of formula (I) indicated by the glucopyranosyl derivative or its pharmaceutically acceptable salt or all of its stereoisomers, or containing the pharmaceutical composition and said derivative and pharmaceutical composition for the preparation of a medicine for treating diabetes and diabetes related diseases of the use. (by machine translation)
NOVEL POLYMORPHIC FORMS OF ((1S,2S,3S,4R,5S))-2,3,4-(TRIS-BENZYLOXY)-5-(4-CHLORO-3-(4-ETHOXY-BENZYL)PHENYL)-6,8-DIOXA-BICYCLO[3.2.1]OCT-1-YL-METHANOL
-
Page/Page column 9; 10, (2018/03/25)
The present invention relates to novel polymorph of (( 1 S.2S.3S,4R,5S))-2,3,4-(tris- benzyloxy)-5-(4-chloro-3-(4-ethoxy-benzyl)phenyl)-6,8-dioxa-bicyclo[3.2.1]oct-1 -yl- methanol of formula (I) wherein Bn refers to benzyl. Characterized by X-ray powder diffraction pattern peaks selected form 5.7, 14.0, 15.6, 15.9, 17.3, 18.8, 19.7, 19.8, 23.0 ±0.2° 2θ. and DSC isothermal peak ranging between 99- 103°C. The invention also relates to process for the preparation of said novel crystalline Form designated as Form-G of ((1S,2S,3S,4R,5S))-2,3,4-(tris-benzyloxy)-5-(4-chloro-3-(4-ethoxy- benzyl)phenyl)-6,8-dioxa-bicyclo[3.2.1]oct-1-yl-methanol of formula (I). This compound of Formula (I) is useful as an intermediate in the preparation of Ertugliflozin, which is used in the treatment of type 2 diabetes mellitus.
Studies towards the synthesis of ertugliflozin from L-Arabinose
Triantakonstanti, Virginia V.,Mountanea, Olga G.,Papoulidou, Kyriaki-Eleni C.,Andreou, Thanos,Koftis, Theocharis V.,Gallos, John K.
, p. 5700 - 5708 (2018/08/20)
A new method for the diastereoselective synthesis of enantiomerically pure ertugliflozin was developed. The crucial step involves an aldol condensation between 1-(4-chloro-3-(4-ethoxybenzyl)phenyl)ethanone and (4R,5R)-5-(((tert-butyldimethylsilyl)oxy)methyl)-2,2-dimethyl-5-((trityloxy)methyl)-1,3-dioxolane-4-carbaldehyde, which was prepared from known 2-C-trityloxymethyl-2,3-O-isopropylidene-L-erythrose (easily accessible in three steps from L-arabinose) by standard reduction/oxidation and protection/deprotection manipulations. Dihydroxylation of the aldol condensation product and further global deprotection led to the formation of the target molecule.
Preparation method of sodium-glucose cotransporter 2 inhibitor
-
Paragraph 0066-0068, (2018/04/03)
The invention discloses a preparation method of a sodium-glucose cotransporter 2 inhibitor. The preparation method specifically relates to a reaction step for converting a compound of a formula III into a compound of a formula II by a 'one-pot method' in a palladium carbon/acid or 1,2-dichlorobenzene catalytic system, wherein the definition of each substituent in the formula II and the formula IIIare the same as that in the description. The method has simple operation and low cost, and is suitable for large-scale production.
PROCESSES FOR THE PREPARATION OF ERTUGLIFLOZIN
-
Paragraph 0144, (2018/01/04)
The present invention relates to processes for the preparation of ertugliflozni. The present invention also provides compounds of Formula (III), Formula (IV), and Formula (VII), processes for their preparation, and their use for the preparation of ertugliflozin. The processes of the present invention involve protecting the ertugliflozin intermediate compound with a suitable protecting group which provides ertugliflozin having high purity and yield.
Preparation method of ertugliflozin and intermediate of ertugliflozin
-
Paragraph 0065; 0066; 0067; 0068, (2018/03/28)
The invention provides a synthesis method of ertugliflozin. The route relates to a new intermediate compound 3 and a compound 5, an SGLT-2 inhibitor ertugliflozin is prepared by virtue of the new intermediate compound 3 and the compound 5, and the preparation method is simple in process route, low in cost and applicable to industrial production. (The compound 3 and the compound 5 are described in the specification.).